Literature DB >> 23864699

Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.

Stefen Brady1, Waney Squier, David Hilton-Jones.   

Abstract

BACKGROUND AND
OBJECTIVE: Historically, the diagnosis of sporadic inclusion body myositis (IBM) has required the demonstration of the presence of a number of histopathological findings on muscle biopsy--namely, rimmed vacuoles, an inflammatory infiltrate with invasion of non-necrotic muscle fibres (partial invasion) and amyloid or 15-18 nm tubulofilamentous inclusions (Griggs criteria). However, biopsies of many patients with clinically typical IBM do not show all of these histopathological findings, at least at presentation. We compared the clinical features at presentation and during the course of disease in 67 patients with histopathologically diagnosed IBM and clinically diagnosed IBM seen within a single UK specialist muscle centre. METHODS AND
RESULTS: At presentation, using clinically focused diagnostic criteria (European Neuromuscular Centre (ENMC) 2011), a diagnosis of IBM was made in 88% of patients whereas 76% fulfilled the 1997 ENMC criteria and only 27% satisfied the histopathologically focused Griggs criteria. There were no differences in clinical features or outcomes between clinically and histopathologically diagnosed patients, but patients lacking the classical histopathological finding of rimmed vacuoles were younger, suggesting that rimmed vacuoles may be a later feature of the disease.
CONCLUSIONS: These findings have important implications for diagnosis and future studies or trials in IBM as adherence to histopathologically focused diagnostic criteria will exclude large numbers of patients with IBM. Importantly, those excluded may be at an earlier stage of the disease and more amenable to treatment.

Entities:  

Keywords:  Incl Body Myositis; Muscle Disease

Mesh:

Substances:

Year:  2013        PMID: 23864699     DOI: 10.1136/jnnp-2013-305690

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Sporadic inclusion body myositis: new insights and potential therapy.

Authors:  Pedro M Machado; Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

Review 2.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

Review 3.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 4.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

5.  Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Authors:  Thomas E Lloyd; Lisa Christopher-Stine; Iago Pinal-Fernandez; Eleni Tiniakou; Michelle Petri; Alan Baer; Sonye K Danoff; Katherine Pak; Livia A Casciola-Rosen; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

Review 6.  [Myositides: What is the current situation?].

Authors:  K M Rösler; O Scheidegger
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

Review 7.  Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature.

Authors:  George K Papadimas; Charalampos Kokkinis; Sophia Xirou; Margarita Chrysanthou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Rheumatol Int       Date:  2019-05-04       Impact factor: 2.631

8.  PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Authors:  David F Fiorentino; Matthew Presby; Alan N Baer; Michelle Petri; Kerri E Rieger; Mark Soloski; Antony Rosen; Andrew L Mammen; Lisa Christopher-Stine; Livia Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2015-08-07       Impact factor: 19.103

Review 9.  Evaluation and construction of diagnostic criteria for inclusion body myositis.

Authors:  Thomas E Lloyd; Andrew L Mammen; Anthony A Amato; Michael D Weiss; Merrilee Needham; Steven A Greenberg
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

Review 10.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.